{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:24:06Z","timestamp":1792081446195,"version":"4.4.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82188102"],"award-info":[{"award-number":["82188102"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-76959-6","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:06:07Z","timestamp":1787385967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CX3CR1\u207a CD8\u207a cytotoxic T cells drive tumor killing in esophageal squamous cell carcinoma during neoadjuvant therapy"],"prefix":"10.1038","volume":"17","author":[{"given":"Yahui","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1407-1267","authenticated-orcid":false,"given":"Songming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongtong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoren","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4242-033X","authenticated-orcid":false,"given":"Zhihua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"76959_CR1","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","volume":"37","author":"LM McLane","year":"2019","unstructured":"McLane, L. M., Abdel-Hakeem, M. S. & Wherry, E. J. CD8 T cell exhaustion during chronic viral infection and cancer. Annu. Rev. Immunol. 37, 457\u2013495 (2019).","journal-title":"Annu. Rev. Immunol."},{"key":"76959_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56\u201361 (2015).","journal-title":"Science"},{"key":"76959_CR3","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","volume":"163","author":"E Morgan","year":"2022","unstructured":"Morgan, E. et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology 163, 649\u2013658.e2 (2022).","journal-title":"Gastroenterology"},{"key":"76959_CR4","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/ijc.34301","volume":"152","author":"H Zhu","year":"2023","unstructured":"Zhu, H. et al. Esophageal cancer in China: practice and research in the new era. Int. J. Cancer 152, 1741\u20131751 (2023).","journal-title":"Int. J. Cancer"},{"key":"76959_CR5","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1053\/j.gastro.2017.08.023","volume":"154","author":"CC Abnet","year":"2018","unstructured":"Abnet, C. C., Arnold, M. & Wei, W. Q. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology 154, 360\u2013373 (2018).","journal-title":"Gastroenterology"},{"key":"76959_CR6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41591-022-02179-2","volume":"29","author":"Y Song","year":"2023","unstructured":"Song, Y. et al. First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial. Nat. Med. 29, 473\u2013482 (2023).","journal-title":"Nat. Med."},{"key":"76959_CR7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","volume":"40","author":"ZX Wang","year":"2022","unstructured":"Wang, Z. X. et al. Toripalimab plus chemotherapy in treatment-na\u00efve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial. Cancer Cell 40, 277\u2013288.e3 (2022).","journal-title":"Cancer Cell"},{"key":"76959_CR8","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jama.2021.12836","volume":"326","author":"H Luo","year":"2021","unstructured":"Luo, H. et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. Jama 326, 916\u2013925 (2021).","journal-title":"Jama"},{"key":"76959_CR9","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun, J. M. et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398, 759\u2013771 (2021).","journal-title":"Lancet"},{"key":"76959_CR10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki, Y. et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N. Engl. J. Med. 386, 449\u2013462 (2022).","journal-title":"N. Engl. J. Med."},{"key":"76959_CR11","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1038\/s41591-024-03064-w","volume":"30","author":"J Qin","year":"2024","unstructured":"Qin, J. et al. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial. Nat. Med. 30, 2549\u20132557 (2024).","journal-title":"Nat. Med."},{"key":"76959_CR12","doi-asserted-by":"publisher","first-page":"e2239778","DOI":"10.1001\/jamanetworkopen.2022.39778","volume":"5","author":"F Ge","year":"2022","unstructured":"Ge, F. et al. Evaluation of clinical and safety outcomes of neoadjuvant immunotherapy combined with chemotherapy for patients with resectable esophageal cancer: a systematic review and meta-analysis. JAMA Netw. Open 5, e2239778 (2022).","journal-title":"JAMA Netw. Open"},{"key":"76959_CR13","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998\u20131013.e20 (2018).","journal-title":"Cell"},{"key":"76959_CR14","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251\u20131259 (2019).","journal-title":"Nat. Med."},{"key":"76959_CR15","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41591-021-01323-8","volume":"27","author":"A Bassez","year":"2021","unstructured":"Bassez, A. et al. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nat. Med. 27, 820\u2013832 (2021).","journal-title":"Nat. Med."},{"key":"76959_CR16","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","volume":"39","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell 39, 1578\u20131593.e8 (2021).","journal-title":"Cancer Cell"},{"key":"76959_CR17","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s43018-021-00292-8","volume":"3","author":"B Liu","year":"2022","unstructured":"Liu, B. et al. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nat. Cancer 3, 108\u2013121 (2022).","journal-title":"Nat. Cancer"},{"key":"76959_CR18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","volume":"557","author":"Y Simoni","year":"2018","unstructured":"Simoni, Y. et al. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575\u2013579 (2018).","journal-title":"Nature"},{"key":"76959_CR19","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","volume":"24","author":"DS Thommen","year":"2018","unstructured":"Thommen, D. S. et al. A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat. Med. 24, 994\u20131004 (2018).","journal-title":"Nat. Med."},{"key":"76959_CR20","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41586-021-03752-4","volume":"596","author":"JX Caushi","year":"2021","unstructured":"Caushi, J. X. et al. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature 596, 126\u2013132 (2021).","journal-title":"Nature"},{"key":"76959_CR21","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/s43018-022-00433-7","volume":"3","author":"B Liu","year":"2022","unstructured":"Liu, B., Zhang, Y., Wang, D., Hu, X. & Zhang, Z. Single-cell meta-analyses reveal responses of tumor-reactive CXCL13(+) T cells to immune-checkpoint blockade. Nat. Cancer 3, 1123\u20131136 (2022).","journal-title":"Nat. Cancer"},{"key":"76959_CR22","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1002\/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C","volume":"73","author":"AM Mandard","year":"1994","unstructured":"Mandard, A. M. et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73, 2680\u20132686 (1994).","journal-title":"Cancer"},{"key":"76959_CR23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nature20805","volume":"541","author":"N Cancer Genome Atlas Research","year":"2017","unstructured":"Cancer Genome Atlas Research, N. et al. Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169\u2013175 (2017).","journal-title":"Nature"},{"key":"76959_CR24","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41422-020-0333-6","volume":"30","author":"Y Cui","year":"2020","unstructured":"Cui, Y. et al. Whole-genome sequencing of 508 patients identifies key molecular features associated with poor prognosis in esophageal squamous cell carcinoma. Cell Res. 30, 902\u2013913 (2020).","journal-title":"Cell Res."},{"key":"76959_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2022.12.004","volume":"41","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma. Cancer Cell 41, 181\u2013195.e9 (2023).","journal-title":"Cancer Cell"},{"key":"76959_CR26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"76959_CR27","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","volume":"184","author":"K Litchfield","year":"2021","unstructured":"Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184, 596\u2013614.e14 (2021).","journal-title":"Cell"},{"key":"76959_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41586-022-04735-9","volume":"606","author":"M Luksza","year":"2022","unstructured":"Luksza, M. et al. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature 606, 389\u2013395 (2022).","journal-title":"Nature"},{"key":"76959_CR29","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41588-023-01499-4","volume":"55","author":"PMK Westcott","year":"2023","unstructured":"Westcott, P. M. K. et al. Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity. Nat. Genet. 55, 1686\u20131695 (2023).","journal-title":"Nat. Genet."},{"key":"76959_CR30","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41588-023-01313-1","volume":"55","author":"L Zapata","year":"2023","unstructured":"Zapata, L. et al. Immune selection determines tumor antigenicity and influences response to checkpoint inhibitors. Nat. Genet. 55, 451\u2013460 (2023).","journal-title":"Nat. Genet."},{"key":"76959_CR31","unstructured":"Tickle, T., Tirosh, I., Georgescu, C., Brown, M. & Haas, B. inferCNV of the Trinity CTAT Project. Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA https:\/\/github.com\/broadinstitute\/inferCNV (2019)."},{"key":"76959_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvr.2021.200231","volume":"13","author":"S Li","year":"2022","unstructured":"Li, S. et al. Oesophageal carcinoma: the prevalence of DNA tumour viruses and therapy. Tumour Virus Res. 13, 200231 (2022).","journal-title":"Tumour Virus Res."},{"key":"76959_CR33","doi-asserted-by":"crossref","unstructured":"Chang, C. & Worrell, S. G. Viruses and esophageal cancer. Dis. Esophagus 33, doaa036 (2020).","DOI":"10.1093\/dote\/doaa036"},{"key":"76959_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202204565","volume":"10","author":"Y Jia","year":"2023","unstructured":"Jia, Y. et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in esophageal squamous cell carcinoma. Adv. Sci. 10, e2204565 (2023).","journal-title":"Adv. Sci."},{"key":"76959_CR35","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.cell.2020.11.019","volume":"183","author":"M Buggert","year":"2020","unstructured":"Buggert, M. et al. The identity of human tissue-emigrant CD8(+) T cells. Cell 183, 1946\u20131961.e15 (2020).","journal-title":"Cell"},{"key":"76959_CR36","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-018-0694-x","volume":"564","author":"L Zhang","year":"2018","unstructured":"Zhang, L. et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature 564, 268\u2013272 (2018).","journal-title":"Nature"},{"key":"76959_CR37","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ccell.2022.03.012","volume":"40","author":"KI Hanada","year":"2022","unstructured":"Hanada, K. I. et al. A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers. Cancer Cell 40, 479\u2013493.e6 (2022).","journal-title":"Cancer Cell"},{"key":"76959_CR38","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1126\/science.abl5447","volume":"375","author":"FJ Lowery","year":"2022","unstructured":"Lowery, F. J. et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science 375, 877\u2013884 (2022).","journal-title":"Science"},{"key":"76959_CR39","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ccell.2022.03.005","volume":"40","author":"C Zheng","year":"2022","unstructured":"Zheng, C. et al. Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers. Cancer Cell 40, 410\u2013423.e7 (2022).","journal-title":"Cancer Cell"},{"key":"76959_CR40","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03704-y","volume":"596","author":"G Oliveira","year":"2021","unstructured":"Oliveira, G. et al. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature 596, 119\u2013125 (2021).","journal-title":"Nature"},{"key":"76959_CR41","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2018.11.043","volume":"176","author":"H Li","year":"2019","unstructured":"Li, H. et al. Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell 176, 775\u2013789.e18 (2019).","journal-title":"Cell"},{"key":"76959_CR42","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2019.10.003","volume":"179","author":"Q Zhang","year":"2019","unstructured":"Zhang, Q. et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell 179, 829\u2013845.e20 (2019).","journal-title":"Cell"},{"key":"76959_CR43","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1182\/bloodadvances.2020001797","volume":"4","author":"RK Das","year":"2020","unstructured":"Das, R. K., O\u2019Connor, R. S., Grupp, S. A. & Barrett, D. M. Lingering effects of chemotherapy on mature T cells impair proliferation. Blood Adv. 4, 4653\u20134664 (2020).","journal-title":"Blood Adv."},{"key":"76959_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","volume":"29","author":"K Kohli","year":"2022","unstructured":"Kohli, K., Pillarisetty, V. G. & Kim, T. S. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther. 29, 10\u201321 (2022).","journal-title":"Cancer Gene Ther."},{"key":"76959_CR45","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41568-023-00635-w","volume":"24","author":"TR Mempel","year":"2024","unstructured":"Mempel, T. R., Lill, J. K. & Altenburger, L. M. How chemokines organize the tumour microenvironment. Nat. Rev. Cancer 24, 28\u201350 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"76959_CR46","first-page":"2587","volume":"141","author":"M Biondi","year":"2023","unstructured":"Biondi, M. et al. Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the acute myeloid leukemia burden. Blood\u00a0141, 2587\u20132598 (2023).","journal-title":"Blood"},{"key":"76959_CR47","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1016\/j.ymthe.2023.09.010","volume":"31","author":"R Sun","year":"2023","unstructured":"Sun, R. et al. CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3\/NF-\u03baB\/SDF-1\u03b1 axis to enhance efficacy against pancreatic cancer. Mol. Ther. 31, 3193\u20133209 (2023).","journal-title":"Mol. Ther."},{"key":"76959_CR48","doi-asserted-by":"crossref","unstructured":"Yamauchi, T. et al. CX3CR1-CD8+ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment. JCI Insight 5, e133920 (2020).","DOI":"10.1172\/jci.insight.133920"},{"key":"76959_CR49","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00262-021-02969-6","volume":"71","author":"T Yamauchi","year":"2022","unstructured":"Yamauchi, T. et al. CD40 and CD80\/86 signaling in cDC1s mediate effective neoantigen vaccination and generation of antigen-specific CX3CR1(+) CD8(+) T cells. Cancer Immunol. Immunother. 71, 137\u2013151 (2022).","journal-title":"Cancer Immunol. Immunother."},{"key":"76959_CR50","doi-asserted-by":"publisher","first-page":"782852","DOI":"10.3389\/fimmu.2021.782852","volume":"12","author":"GAF Vitiello","year":"2021","unstructured":"Vitiello, G. A. F., Ferreira, W. A. S., Cordeiro de Lima, V. C. & Medina, T. D. S. Antiviral responses in cancer: boosting antitumor immunity through activation of interferon pathway in the tumor microenvironment. Front. Immunol. 12, 782852 (2021).","journal-title":"Front. Immunol."},{"key":"76959_CR51","doi-asserted-by":"publisher","first-page":"e1011982","DOI":"10.1371\/journal.ppat.1011982","volume":"20","author":"P Steinbach","year":"2024","unstructured":"Steinbach, P. et al. Influenza virus infection enhances tumour-specific CD8+ T-cell immunity, facilitating tumour control. PLoS Pathog. 20, e1011982 (2024).","journal-title":"PLoS Pathog."},{"key":"76959_CR52","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4352","volume":"349","author":"K Lim","year":"2015","unstructured":"Lim, K. et al. Neutrophil trails guide influenza-specific CD8(+) T cells in the airways. Science 349, aaa4352 (2015).","journal-title":"Science"},{"key":"76959_CR53","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.4049\/jimmunol.1401192","volume":"193","author":"DM Durrant","year":"2014","unstructured":"Durrant, D. M., Daniels, B. P. & Klein, R. S. IL-1R1 signaling regulates CXCL12-mediated T cell localization and fate within the central nervous system during West Nile Virus encephalitis. J. Immunol. 193, 4095\u20134106 (2014).","journal-title":"J. Immunol."},{"key":"76959_CR54","doi-asserted-by":"crossref","unstructured":"Yan, Y. et al. CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI Insight 3, e97828 (2018).","DOI":"10.1172\/jci.insight.97828"},{"key":"76959_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43381-1","volume":"14","author":"S Cappuyns","year":"2023","unstructured":"Cappuyns, S. et al. PD-1(-) CD45RA(+) effector-memory CD8 T cells and CXCL10(+) macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma. Nat. Commun. 14, 7825 (2023).","journal-title":"Nat. Commun."},{"key":"76959_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21619-0","volume":"12","author":"T Yamauchi","year":"2021","unstructured":"Yamauchi, T. et al. T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. Nat. Commun. 12, 1402 (2021).","journal-title":"Nat. Commun."},{"key":"76959_CR57","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nmeth.2883","volume":"11","author":"A Roth","year":"2014","unstructured":"Roth, A. et al. PyClone: statistical inference of clonal population structure in cancer. Nat. Methods 11, 396\u2013398 (2014).","journal-title":"Nat. Methods"},{"key":"76959_CR58","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"76959_CR59","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl5197","volume":"376","author":"C Dominguez Conde","year":"2022","unstructured":"Dominguez Conde, C. et al. Cross-tissue immune cell analysis reveals tissue-specific features in humans. Science 376, eabl5197 (2022).","journal-title":"Science"},{"key":"76959_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1891-0","volume":"20","author":"DE Wood","year":"2019","unstructured":"Wood, D. E., Lu, J. & Langmead, B. Improved metagenomic analysis with Kraken 2. Genome Biol. 20, 257 (2019).","journal-title":"Genome Biol."},{"key":"76959_CR61","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41596-024-01045-4","volume":"20","author":"S Jin","year":"2025","unstructured":"Jin, S., Plikus, M. V. & Nie, Q. CellChat for systematic analysis of cell-cell communication from single-cell transcriptomics. Nat. Protoc. 20, 180\u2013219 (2025).","journal-title":"Nat. Protoc."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76959-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76959-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76959-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:47:05Z","timestamp":1790308025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76959-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76959"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76959-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10052"}}